A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies

NCT02963831 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

67

Enrollment

OTHER

Sponsor class

Conditions

Colorectal Cancer
Ovarian Cancer
Appendiceal Cancer

Interventions

BIOLOGICAL: ONCOS-102
DRUG: Durvalumab
DRUG: Cyclophosphamide

Sponsor

Ludwig Institute for Cancer Research

Collaborators

[object Object]
[object Object]
[object Object]